rare disease Archives - Page 20 of 20 -

Examining the impact of support programmes for orphan treatments.

Are European incentives speeding access in rare cancer treatments?

https://pharmaphorum.com/views-and-analysis/european-incentives-speeding-access-rare-cancer-treatments/

Highlighting the symptoms of scleroderma, latest research and a genuine ‘diary’ experience from a US patient.

World Scleroderma Day: raising awareness

https://pharmaphorum.com/views-and-analysis/world-scleroderma-day-raising-awareness/

Martin Mackay, head of R&D at Alexion, talks to pharmaphorum about the company’s research pipeline for severe and

Alexion: aiming to break new ground in ultra-rare therapies

https://pharmaphorum.com/articles/alexion-aiming-to-break-new-ground-in-ultra-rare-therapies/

People wanting to establish rare disease support groups face lack of understanding and awareness from the medical profession,

Rare disease groups: scaling up from the kitchen table

https://pharmaphorum.com/views-and-analysis/rare-disease-groups-scaling-up-from-the-kitchen-table/

With the appraisal process for highly specialised treatments in the UK described by one NHS insider as ‘impenetrable’,

Funding rare disease treatments in the UK – navigating the labyrinth

https://pharmaphorum.com/views-and-analysis/funding-rare-disease-treatments-in-the-uk-navigating-the-labyrinth/

With challenges to highly priced rare disease medicines and the Cancer Drug Fund evolving again – what

Available on-demand: The Price is Right? – Delivering UK access for niche patient populations

https://pharmaphorum.com/debates-insight-market-access/live-webinar-the-price-is-right-uk-niche-market-access/

rare disease